Will this biotech’s cash last until the FDA date?
Survive-to-Event: cash runway vs the next PDUFA, AdCom, or readout. Type a ticker.
CAPR ok
Thesis board →$148M cash · $9M/mo burn · 500d runway · PDUFA 2026-08-22
Cash covers the next gate with ~18 months spare (curated estimate).
Featured races
Tap a disease to see rivals, cash lens, and the next gate.
Upcoming catalysts
Confirmed dates first — open thesis board in one tap.
- 2026-10-18LEGNEarlier-line myeloma updateCompany-guidedcash ok
- 2026-10-20BIIBSubcutaneous / label updateCompany-guidedcash ok
- 2026-10-25AKROPhase 3 histologyCompany-guidedcash ok
- 2026-10-28JANXJANX007 prostate updateCompany-guidedcash ok
- 2026-10-30NTLAPivotal ATTR updateCompany-guidedcash ok
- 2026-11-01LLYPhase 3 obesity readoutCompany-guidedcash ok
- 2026-11-01MDGLLabel / real-world updateCompany-guidedcash ok
- 2026-11-05BMYCAR-T myeloma competitive updateCompany-guidedcash ok
FAQ
What is Survive-to-Event?
Survive-to-Event asks whether a biotech’s reported cash covers the days until its next FDA date, AdCom, or trial readout. BioFin labels the result OK, TIGHT, or BROKEN from curated cash and burn — not audited filings.
Is BioFin investment advice?
No. BioFin is an educational research tracker. Dates change and cash figures are curated estimates. Verify FDA, ClinicalTrials.gov, and SEC sources before any decision.
How do I check a ticker’s cash runway vs PDUFA?
Type a ticker on the BioFin hub. You get cash, monthly burn, days to the next catalyst, and a shareable OK / TIGHT / BROKEN line. Open the thesis board for sources.
Where do PDUFA and catalyst dates come from?
Curated catalysts with a confidence tag: confirmed, company-guided, or estimated. Only treat Confirmed dates as reliable after you open the source link on the calendar or thesis board.